Trial reportNature communications2024
Abstract readClinical Trial, Phase IClinical Trial, Phase II
In one paragraph
Trial report in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- Whole-body CD8Nature communications · 2025Trial
- Bioengineered cell therapies for pediatric solid tumors: unmet needs and a measurement-integrated approach.Progress in biomedical engineering (Bristol, England) · 2026Review
- Improved early response assessment of chemoimmunotherapy efficacy byEuropean journal of nuclear medicine and molecular imaging · 2026Article
- Imaging the hallmarks of cancer.Nature reviews. Cancer · 2026Review
- Article
- CAR-T and TIL therapies in solid tumors: barriers, clinical lessons, and convergent solutions.Cancer cell international · 2026Review
- Immuno-positron emission tomography in cardiovascular disease: Advances, challenges, and opportunities.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2026Review
- Bioorthogonal Fluorogenic Reporters for Noninvasive Imaging and Urinalysis of Immunotherapeutic Response in Renal Cell Carcinoma.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Challenges in tracer development for tumor microenvironment (TME) imaging.European journal of nuclear medicine and molecular imaging · 2026Review
- Gallium-Containing Agents for Tumor Diagnosis and Therapy: Current Status and Future Prospects.Small (Weinheim an der Bergstrasse, Germany) · 2026Review
- Nano-enabled spatially selective protein degradation modulates lactate metabolism to potentiate antitumor immunity in liver cancer.Nature nanotechnology · 2026Article
- Targeting Cytotoxic T-Cell Effector Function with Granzyme B PET: Translational Advances Toward Predicting Immunotherapy Outcomes.Molecular diagnosis & therapy · 2026Review
- ICAM-1 promotes T cell glycolytic reprogramming and tumor infiltration to drive 18F-FDG PET flares following radiotherapy.Protein & cell · 2026Article
- Granzyme B PET/CT predicts chemo-immunotherapy outcomes in microsatellite stable gastric cancers.European journal of nuclear medicine and molecular imaging · 2026Article
- Applications and research progress of PET/CT in dynamic monitoring of immunotherapy in melanoma.Journal of translational medicine · 2026Review
- Metabolic [¹⁸F]F-AraG PET imaging of T Cell activation: a functional complement to cell-specific immune tracers.EJNMMI research · 2026Review
- Companion Diagnostics in Clinical Therapy: Current Applications and Future Directions.MedComm · 2026Review
- Tumour Microenvironment-Informed Radiotheranostics: Why and How Nuclear Medicine Could Advance Precision Oncology in the Decade Ahead.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Positron emission tomography imaging of T-cell activity in cardiovascular disease and its emerging role in imaging adaptive immunity.American journal of nuclear medicine and molecular imaging · 2026Review
- Imaging the fate of CAR-T cellsFrontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Xiuling Shen *Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, 100142, Beijing, China.
Haoyi Zhou *State Key Laboratory of Vascular Homeostasis and Remodeling, Department of Radiation Medicine, School of Basic Medical Sciences, Peking University Health Science Center, 100191, Beijing, China.
Xin ZhouKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, 100142, Beijing, China.
Zongchao LiuState Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Department of Cancer Epidemiology, Peking University Cancer Hospital & Institute, 100142, Beijing, China.ORCID 0000-0002-2008-3793
Xiangxi MengKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, 100142, Beijing, China.ORCID 0000-0002-6590-011X
Linyu ZhangState Key Laboratory of Vascular Homeostasis and Remodeling, Department of Radiation Medicine, School of Basic Medical Sciences, Peking University Health Science Center, 100191, Beijing, China.
Yufei SongKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, 100142, Beijing, China.
Rui GuoKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, 100142, Beijing, China.
Fei WangKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, 100142, Beijing, China.
Kui LiState Key Laboratory of Vascular Homeostasis and Remodeling, Department of Radiation Medicine, School of Basic Medical Sciences, Peking University Health Science Center, 100191, Beijing, China.
Wenqing LiState Key Laboratory of Holistic Integrative Management of Gastrointestinal Cancers, Department of Cancer Epidemiology, Peking University Cancer Hospital & Institute, 100142, Beijing, China.ORCID 0000-0002-8336-5552
Zhi YangKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, 100142, Beijing, China. pekyz@163.com.ORCID 0000-0003-2084-5193
Zhaofei LiuKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, 100142, Beijing, China. liuzf@bjmu.edu.cn.ORCID 0000-0001-8718-8154
Nan LiKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, 100142, Beijing, China. rainbow6283@sina.com.ORCID 0000-0001-8619-7550
Funding
Beijing Nova Program 20220484182National Natural Science Foundation of China (National Science Foundation of China) 81920108020 and 82325028Natural Science Foundation of Beijing Municipality (Beijing Natural Science Foundation) Z220011 and Z220014
Abstract
To tackle the clinical challenge of noninvasively assessing immunotherapy efficacy in patients, here we used positron emission tomography (PET) with
Indexed as
GranzymesImmunotherapyLymphomaPositron-Emission TomographyAdultAgedCD8-Positive T-LymphocytesFemaleGallium RadioisotopesHumansImmune Checkpoint InhibitorsMaleMiddle AgedNeoplasmsProgression-Free SurvivalTissue DistributionGallium RadioisotopesGranzymesGZMB protein, humanImmune Checkpoint Inhibitors
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.